Dialysis patients are high-value customers, costing an estimated $34,000 per year on average. They are a relatively stable customer base which explains how the dialysis industry is noncyclical in nature and is only minimally affected by the vagaries of economic downturns. And despite a relatively small customer base of just over 2 million patients worldwide, the industry has attracted a large number of players, especially in the highly fragmented services segment, which is made up of mostly regional companies.

Consolidation has become a recurring theme in the dialysis sector. Between 2005 and 2011, several structural changes occurred in the industry. Gambro exited the North American dialysis care market by selling its dialysis care division to DaVita, Inc. and Fresenius bought Renal Advantage Inc. to maintain its leadership in North American dialysis care. The company also acquired Hema Metrics Crit-Line system business in early 2011. In 2009, Baxter acquired Edwards CRRT a provider of continuous renal replacement therapy.

This new report, “World Market for Dialysis Equipment and Services”, examines in detail both the dialysis products industry with its demand structure and major trends affecting it, and the services industry and its composition. Profiles of the major competitors are included, along with key market data and growth forecasts.

The world market for products that treat wounds grew 6.2% in 2010 and is expected to grow nearly 7% this year. An aging population and an increased in diabetes incidence have driven growth, but a host of new approaches and a coming-of-age of recent innovations are the greatest factors driving growth. Therapy using vacuums, novel ingredients such as silver and honey, and moist dressings are among the new technologies driving the wound care market.

Wounds are known to heal better in a vacuum than in a normal atmosphere, and thus negative pressure wound therapy (NPWT) devices that can create a vacuum around the wound area continue to see sales growth. Moist dressings using hydrocolloids intended to stick to wounds but not dry them out, or hydrogels which help sooth nerve endings, are also product categories-to-watch, according to the report. Companies that offer moist dressing products include 3M, ConvaTec, B. Braun and Systagenix. Silver-based products also saw expansion last year. Smith & Nephew’s Allevyn Ag line, containing antimicrobial silver, saw two recent product extensions including a ‘gentle’ version.

The worldwide wound care market reached revenues of $14.9 billion in 2010; this is based on sales at the manufacturers’ level. The market was varied in terms of both product offerings and product maturity.

The market potential for advanced wound care products are detailed in Kalorama Information’s Wound Care 2011, a complete look at the wound care industry. This is one of the few reports on the wound care industry to break out the market by application area - wound care for the treatment of burns, wound care for the treatment of skin ulcers, and wound care for surgical concerns.

As part of its coverage of the market today, this report includes:

• Description of Wound Care Products and Innovations
• World Wound Care Products Market Size and Forecast to 2015
• Reimbursement Trends in the US and Other Countries
• Key Industry Developments and Trends
• Competitor Profiles
• Types of Wounds and Treatment
• Current Market Sizes by Application Area (Burns, Skin Ulcers, Surgical and Trauma Wounds), Product Type and Country/Region
• Regional Breakout of Market (US, Europe, Asia, ROW)
• Competitive Analysis and Market Share

As part of its coverage, the report also has current market size numbers for the following wound care product categories:

• Anti Infectives
• Cleansing
• Debridement
• Dry Dressings/Bandages,
• Moist Dressings
• Biological Dressings
• Pressure Relief
• Negative Pressure Therapy
• Sutures
• Staples
• Adhesives/Sealants
• Tapes
• Miscellaneous Treatments

Besides the always-improving synthetic dressing materials, newer technologies in wound treatment include the xenogeneic tissue scaffold, bilayered human dermal substitutes, recombinant growth factors, endoscopic subfascial ligation of venous perforators, and endovascular arterial repair techniques. New wound care products and devices are entering the market with lightening speed, all striving for the best clinical outcomes.

The definitions stated below should be able to clear these misconceptions and worries on president Obama role in the Health Insurance Reform:

1.    Government-Run Health Care System - Doctors are concerned as government employees working in hospitals that are run by the government organizations.

2.    Public Option - Government will fund an insurance plan to compete with the private funded insurance plans present in the current market.

3.    Single Payer - Under this option no premiums are require, every individual is cover irrespective of their age and income. Doctors and hospitals will remain private.

Always keep in mind that health care debates are generally not trying to change everything that has long been followed. No one wants an entire government run health care system. In case anyone is ever stating these statements, then you can always be sure that they certainly are trying to mislead people.

Most of the public opinion has always been argued and talked about is definitely the government run plan which competes with the private plans. Both will certainly let you make your own choice of a doctor. So when comparing to present insurance plans, the public option certainly does not let anyone discriminate the already existing conditions. It allowed anyone to have health care insurance plans and at the same time controlling the cost of health care.

But you can always be sure of one thing, that is the public option certainly does not warrant any support that is in fact unconditional. In spite of everything and it benefits, this may never be able to stand next to private plans because of cost. There still shall be administrative expenses and this can be estimated to nearly billions every year.

When speaking of the single payer system it only focuses on health care and drives profits away. The result is that government has to pay for all the health care instead of the insurance companies by the means of taxes. Under these circumstances both medical institutions and doctors shall be private and independent of government. Most of the Americans can still pick up their own doctors. This system of health care eliminates most of the insurance companies, as without the presence of any private organization most of the money may only be spent on advertisements and bonuses for CEO and managers. But all this is put in for health care for patients and also tax payers. This policy may certainly improve the condition of finance and health care for Americans.

How much would this system actually save? It is an estimate value of $387 billion yearly based on H.R. 676. So for nearly 95% of Americans the cost of single payer would be very much less as compared to paying insurance to private companies. A number of researches conducted by Dean Baker, (co-founder/Co-director) C.E.P.R (center for research and economics) stated that in case of single payer a family consisting of three members would have outspend around $1900 on health coverage by means of taxes and not $11,000 by means of premiums.

A number of other studies conducted by Lewin group stated that this system of single payer certainly would reduce the cost of administration to save money for Americans. Near 59% of Americans do support single payer according to Reuters.

In case you want to give private insurance companies a halt then single payer is the only solution and this is also considered as most effective and democratic solution to approach health care debates.

There are a number of factors that actually pull the public support away from single payer system like aggressive public campaign, and less media coverage. But a single payer bill like H.R. 676 has also been supported by John Conyers, D-Mich, who is a representative and shall also be presented in the House.

According to the researchers, a Mediterranean diet also leads to more weight loss, better control over the blood sugar levels, reduction in the risks of developing heart disease and lessen dependence upon medicines for lowering blood sugar levels. Dottore Dario Giugliano of Second University of Naples, Southern Italy, led the study which involved more than 200 men and women suffering from Type 2 diabetes. These people were provided with regular counseling by the professional nutritionists and they were asked to either follow a low carb Mediterranean diet or a low fat diet for a period of 4 years.

Results from the study showed that only 44% of the people who took Mediterranean diet still require medicine for lowering down their blood sugar levels compare to 70% for who took the low fat diet. The group who took Mediterranean diet also lose more weight, have thinner waists, and showed an increase in good cholesterol level and decrease in the harmful triglycerides.

Giugliano further explained that results of this study accentuate the significance of healthy lifestyle and how it affects people’s health. He added that it is necessary not to ignore the healthy eating habits, despite the fact that several medicines are now available for controlling blood sugar levels in diabetic patients.

Many experts believe that if people are given the choice to eat a low fat diet, a low calorie diet or a low carbohydrate Mediterranean diet, most of them will choose the latter because it is much tastier and has more variety. With the positive results from this research on controlling blood sugar levels, it is expected that many more people with diabetes will be following the diet. If you are suffering from diabetes and would like to try on the diet, it is advice that you check with qualified doctor or nutritionist before changing your diet patterns.

According to the study, the juice extracted from the North American lowbush blueberries, bio-transformed with the bacteria from the berry’s skin, proves to be a great anti-diabetic and anti-obesity agent.

The bio-transformed juices were compared to the regular blueberry drinks and their effects were tested on mice by researchers from University of Montreal, University of Moncton and Institut Armad-Frappier. Dr. Pierre Hadda, the lead author of the study and pharmacology professor in the Faculty of Medicine of the University Montreal says that the results that were derived after the study clearly indicate that the bio-transformed blueberries juice has strong potential against diabetes and obesity.

Haddad said that the bio-transformed juices decrease hyperglycemia in the mice suffering from diabetes and has the ability to protect the young mice from developing diabetes and obesity. The effects of the bio-transformed juices were tested on a mice group that was prone to insulin resistance, hypertension, diabetes and obesity. It was found that by adding bio-transformed juice into the drinking water of the mice, their food intake and also their body weight got reduced.

Bio-transforming the juice from blueberries was achieved with the help of bacteria of a new strain that is isolated from the plant of the blueberry. This is known as serratia vaccinii which, according to the researchers, increases the antioxidant effects of the fruit.

Tri Vuong another leading authors with University of Montreal said that consuming fermented blueberry juice significantly and gradually reduces high glucose levels in the bodies of the diabetic mice. He said that after 3 days consuming the juice, the glycemia levels in the mice subjects were reduced by 35%.